$SCYX

SCYNEXIS INC (SCYX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry JERSEY CITY, N.J., September 22, 2026 – SCYNEXIS, Inc.

SCYNEXIS INC (SCYX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies. JERSEY CITY, N.J., Septembe

SCYNEXIS INC (SCYX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false --12-31 0001178253 0001178253 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J

SCYNEXIS (NASDAQ: SCYX) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-10 to maintain its listing on The Nasdaq Capital Market. The virtual special meeting is scheduled for May 19, 2026, where shareholders will vote on the proposal to increase the per-share price and avoid potential delisting proceedings by June 15, 2026. If approved, the board will have the discretion to determine the exact ratio and implement the split, which will proportionally reduce outstanding shares and adjust equity incentive plans.

JERSEY CITY, N.J., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that a novel series of antifungal compounds utilizing ...

Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company's next generation of triterpenoid antifungals ( fungerps ) .

JERSEY CITY, N.J., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, ...

JERSEY CITY, N.J., Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2025.

JERSEY CITY, N.J., May 28, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, ...

JERSEY CITY, N.J., May 15, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2025.